<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822638</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0412</org_study_id>
    <nct_id>NCT02822638</nct_id>
  </id_info>
  <brief_title>Cohort of STEMI Patients</brief_title>
  <acronym>STEMI</acronym>
  <official_title>CoHort of STEMI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic heart disease is the leading cause of mortality in industrialized countries. ST&#xD;
      elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In&#xD;
      the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely&#xD;
      reperfusion (primary percutaneous intervention) and significant progression in pharmacologic&#xD;
      intervention.&#xD;
&#xD;
      However, death and heart failure incidence after STEMI remain elevated: up to 20% at one&#xD;
      year.&#xD;
&#xD;
      Also, therapeutic management following international guidelines is standardized toward a&#xD;
      &quot;one-size fits all&quot; therapeutic management.&#xD;
&#xD;
      In order to continue improving myocardial infarction outcomes, there is a need to better&#xD;
      understand and individualize therapeutic targets such myocardial reperfusion injury, post&#xD;
      reperfusion inflammation, adverse left ventricular (LV) remodeling ….&#xD;
&#xD;
      This knowledge will allow us to propose new therapeutic strategies and in the long run strive&#xD;
      towards personalized medicine.&#xD;
&#xD;
      The aim objective of this cohort of STEMI patients is to identify new biological markers of&#xD;
      injury and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Troponin</measure>
    <time_frame>Day 0</time_frame>
    <description>Dosage of Troponin at hospital admission and 4 hours after Percutaneous coronary intervention (PCI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Creatine Kinase</measure>
    <time_frame>Day 0</time_frame>
    <description>Dosage of Creatine Kinase at hospital admission and 4 hours after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Class</measure>
    <time_frame>at admission (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>24 hours after PCI (Day 1)</time_frame>
    <description>LVEF measured by echocardiography</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1204</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>STEMI PATIENT Cohort</arm_group_label>
    <description>STEMI PATIENT Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STEMI PATIENT Cohort</intervention_name>
    <description>PCI</description>
    <arm_group_label>STEMI PATIENT Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In STEMI patient refered for PCI at Louis Pradel Hospital, blood samples were taken on&#xD;
      admission at (H0) and 4h after reperfusion.&#xD;
&#xD;
      To constitute the serum bank of our STEMI cohort, samples were collected the same time as the&#xD;
      blood tests done routinely.&#xD;
&#xD;
      These additional samples were be centrifuged and treated and stored in a collection of&#xD;
      biological samples of total serum and plasma and blood at the Biological Resource Center of&#xD;
      HCL Neurobiotec at -80 ° C (DC- 2008-72, AC-2013-1867 certified NFS96900 FR13-018140).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        STEMI PATIENT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a&#xD;
             12-lead ECG.&#xD;
&#xD;
          -  Primary PCI within 12 hours of symptoms onset.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of STEMI not confirmed by angiography&#xD;
&#xD;
          -  Refusal to participate in the study or to sign the consent&#xD;
&#xD;
          -  Inability to give information to the subject about the study&#xD;
&#xD;
          -  Lack of medical social coverage&#xD;
&#xD;
          -  Deprivation of civil rights&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel OVIZE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'investigation Clinique , Hôpital Cardiovasculaire Louis Pradel 28, Avenue du Doyen Lépine - 69677 BRON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Cardiovasculaire Louis Pradel 28, Avenue du Doyen Lépine</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>biomarkers</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

